China Resources Pharmaceutical Group (HKSE:03320) Debt-to-Equity : 1.35 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group Debt-to-Equity?

China Resources Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$50,558 Mil. China Resources Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$17,432 Mil. China Resources Pharmaceutical Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$50,270 Mil. China Resources Pharmaceutical Group's debt to equity for the quarter that ended in Dec. 2023 was 1.35.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for China Resources Pharmaceutical Group's Debt-to-Equity or its related term are showing as below:

HKSE:03320' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.68 Med: 1.09 Max: 1.82
Current: 1.35

During the past 11 years, the highest Debt-to-Equity Ratio of China Resources Pharmaceutical Group was 1.82. The lowest was 0.68. And the median was 1.09.

HKSE:03320's Debt-to-Equity is ranked worse than
90.92% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HKSE:03320: 1.35

China Resources Pharmaceutical Group Debt-to-Equity Historical Data

The historical data trend for China Resources Pharmaceutical Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group Debt-to-Equity Chart

China Resources Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.01

0.95

1.12

1.07

1.35

China Resources Pharmaceutical Group Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.12	1.40	1.07	1.52	1.35

Competitive Comparison of China Resources Pharmaceutical Group's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Resources Pharmaceutical Group's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's Debt-to-Equity falls into.

China Resources Pharmaceutical Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

China Resources Pharmaceutical Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(50558.386	+	17431.961)	/	50269.646
	=	1.35

China Resources Pharmaceutical Group's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(50558.386	+	17431.961)	/	50269.646
	=	1.35

China Resources Pharmaceutical Group (HKSE:03320) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

China Resources Pharmaceutical Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Pharmaceutical Group (HKSE:03320) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » Debt-to-Equity

Traded in Other Exchanges

640:Germany

Address

26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG

Website

https://www.crpharm.com

CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.

Executives

Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si

2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines